Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
24
pubmed:dateCreated
2009-11-20
pubmed:abstractText
Chronic immune activation is thought to play a major role in human immunodeficiency virus (HIV) pathogenesis, but the relative contributions of multiple factors to immune activation are not known. One proposed mechanism to protect against immune activation is the ability of Nef proteins from some HIV and simian immunodeficiency virus strains to downregulate the T-cell receptor (TCR)-CD3 complex of the infected cell, thereby reducing the potential for deleterious activation. HIV type 1 (HIV-1) Nef has lost this property. In contrast to HIV-1, HIV-2 infection is characterized by a marked disparity in the disease course, with most individuals maintaining a normal life span. In this study, we examined the relationship between the ability of HIV-2 Nef proteins to downregulate the TCR and immune activation, comparing progressors and nonprogressors. Representative Nef variants were isolated from 28 HIV-2-infected individuals. We assessed their abilities to downregulate the TCR from the surfaces of CD4 T cells. In the same individuals, the activation of peripheral lymphocytes was evaluated by measurement of the expression levels of HLA-DR and CD38. We observed a striking correlation of the TCR downregulation efficiency of HIV-2 Nef variants with immune activation in individuals with a low viral load. This strongly suggests that Nef expression can influence the activation state of the immune systems of infected individuals. However, the efficiency of TCR downregulation by Nef was not reduced in progressing individuals, showing that TCR downregulation does not protect against progression in HIV-2 infection.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-10361237, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-10627569, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-11061648, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-11724830, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-11744830, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-11986671, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-12487822, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-12648460, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-14960472, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-14984439, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-15168740, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-15280498, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-15858014, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-16218803, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-16520776, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-16777597, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-17190786, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-17237418, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-17375091, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-17823657, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-17846036, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-18171295, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-18636106, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-2786147, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-8397950, http://linkedlifedata.com/resource/pubmed/commentcorrection/19812166-9820147
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1098-5514
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
83
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
12968-72
pubmed:dateRevised
2010-9-27
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Downregulation of the T-cell receptor by human immunodeficiency virus type 2 Nef does not protect against disease progression.
pubmed:affiliation
Institut Pasteur, Virologie, 28 rue du Dr. Roux, Paris, France. jfeldman@pasteur.fr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't